The University of Texas M.D. Anderson Cancer Center is proposing a Specialized Program of Research Excellence (SPORE) in Leukemia. The primary goal of this Leukemia SPORE is to cultivate and facilitate innovative and significant translational research in the biologic, genetic and clinical aspects of leukemia to improve understanding, therapy, and prognosis. The multidisciplinary group of investigators in the Leukemia SPORE will accomplish this goal through effective integration of laboratory, epidemiologic and clinical investigations. Such activity will further our understanding of genetic susceptibility and leukemogenic molecular processes in leukemia, leading to novel, molecularly targeted strategies in leukemia. The SPORE is designed with 6 research projects and 3 core resources, as well as programs for developmental research and career development. The research projects are designed to target specific areas important in leukemia. ? Project 1 - Epigenetics of Drug Resistance in Acute Leukemia -targets methylation for therapy in leukemia ? Project 2 -Adoptive Cellular Therapy of Myeloid Leukemia - targets the use of MPO-Specific Cytotoxic T Lymphocytes (CTL) to treat leukemia ? Project 3 - Concerted Blockade of Oncoprotein Activity - targets sequential DNA, RNA and oncoprotein blockage in leukemia ? Project 4 -PPAR-gamma Nuclear Transcription Factor: A Novel Target for Leukemia Therapy - targets PPAR-gamma expression for leukemia therapy ? Project 5 - Molecular Epidemiology of AML Risk and Progression - evaluates genetic-molecular susceptibilities to development of AML through studies of relevant detoxifying and carcinogenesis-promoting pathways ? Project 6 - Response of AML Patients to FLT3 Inhibitors - targets FLT3 ligand inhibition in leukemias expressing FLT3 mutations or internal tandem duplication (ITD) ? Core and other resources are: Core A - Administration, Core B - Pathology and Tissue, Core C - Biostatistics & Data Management, Developmental Research Program, and Career Development Program. Through this leukemia SPORE, our research team will make a significant impact on leukemia prognosis. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-03
Application #
6937763
Study Section
Special Emphasis Panel (ZCA1-GRB-G (J1))
Program Officer
Nothwehr, Steven F
Project Start
2003-08-05
Project End
2008-04-30
Budget Start
2005-07-29
Budget End
2006-04-30
Support Year
3
Fiscal Year
2005
Total Cost
$2,492,247
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Masarova, Lucia; Verstovsek, Srdan; Hidalgo-Lopez, Juliana E et al. (2018) A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132:1664-1674
Good, Charly Ryan; Panjarian, Shoghag; Kelly, Andrew D et al. (2018) TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Res 78:4126-4137
Choi, Sangbum; Kang, Sangwook; Huang, Xuelin (2018) Smoothed quantile regression analysis of competing risks. Biom J 60:934-946
Boddu, Prajwal; Kantarjian, Hagop; Garcia-Manero, Guillermo et al. (2018) The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59:790-802
Yang, Tian-Hui; St John, Lisa S; Garber, Haven R et al. (2018) Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201:1389-1399
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :

Showing the most recent 10 out of 487 publications